Abstract:Introduction: Structure-based drug design is a wide area of identification of selective inhibitors of a target of interest. From the time of the availability of three dimensional structure of the drug targets, mostly the proteins, many computational methods had emerged to address the challenges associated with drug design process. Particularly, drug-likeness, druggability of the target protein, specificity, off-target binding, etc., are the important factors to determine the efficacy of new chemical inhibitors. Objective: The aim of the present research was to improve the drug design strategies in field of design of novel inhibitors with respect to specific target protein in disease pathology. Recent statistical machine learning methods applied for structural and chemical data analysis had been elaborated in current drug design field. Methods: As the size of the biological data shows a continuous growth, new computational algorithms and analytical methods are being developed with different objectives. It covers a wide area, from protein structure prediction to drug toxicity prediction. Moreover, the computational methods are available to analyze the structural data of varying types and sizes of which, most of the semi-empirical force field and quantum mechanics based molecular modeling methods showed a proven accuracy towards analysing small structural data sets while statistics based methods such as machine learning, QSAR and other specific data analytics methods are robust for large scale data analysis. Results: In this present study, the background has been reviewed for new drug lead development with respect specific drug targets of interest. Overall approach of both the extreme methods were also used to demonstrate with the plausible outcome. Conclusion: In this chapter, we focus on the recent developments in the structure-based drug design using advanced molecular modeling techniques in conjunction with machine learning and other data analytics methods. Natural products based drug discovery is also discussed.

Computational Methods for Structure-Based Drug Design Through System Biology.

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

Structure-Based Approach For In-Silico Drug Designing

Structure-Based Drug Design Strategies and Challenges

Recent Trends in Drug Design and Discovery

Towards Structure-Based Protein Drug Design

Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery

Targeted Molecular Diversity in Drug Discovery: Integration of Structure-Based Design and Combinatorial Chemistry

Systematic computational strategies for identifying protein targets and lead discovery

Recent Advances in Automated Structure-Based De Novo Drug Design

Structure-based drug design: From nucleic acid to membrane protein targets

Computational approaches streamlining drug discovery

Molecular Docking and Structure-Based Drug Design Strategies

Structure-Based Virtual Screening of Chemical Libraries for Drug Discovery

Computer Aided Drug Design for Multi-Target Drug Design: SAR /QSAR, Molecular Docking and Pharmacophore Methods.

Computer Aided Drug Design: Success and Limitations.

Current Developments of Computer-Aided Drug Design

Structure-based drug design: aiming for a perfect fit

Bioinformatics Techniques For Drug Discovery: Applications For Complex Diseases